InVivoPlus anti-mouse CTLA-4 (CD152) BP0164-R050mg from Bio X Cell

Product Specs
ItemInVivoPlus anti-mouse CTLA-4 (CD152)
CompanyBio X Cell
Price $4,508.50Supplier Page View Company Product Page
Catalog NumberBP0164-R050mg
Quantity50 mg
Applicationsin vivo Neutralization & Blocking, Western Blot, in vitro Organoids/Organ-on-Chip
ConcentrationLot-Specific
Conjugate/TagUnconjugated
FormatPBS, pH 7.0, Contains no stabilizers or preservatives, Liquid
Purity≥95% Determined by SDS-PAGE
Reactivitymouse
IsotypeIgG2b
Clone9D9
Hostmouse
Antibody TypePrimary Antibody
NCBI Full Gene Namecytotoxic T-lymphocyte-associated protein 4
NCBI Gene AliasesCd152, Ctla-4, Ly-56
ClonalityMonoclonal
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology, CD Markers
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze
ImmunogenNot available or unknown
Molecular Weight150 kDa
ModificationsNo
OriginUnited States

Endotoxin: ≤0.5EU/mg (≤0.0005EU/µg), Determined by LAL gel clotting assay

Quantities Available: 5mg, 25mg, 50mg, 100mg, Additional Custom Sizing Available on bioxcell.com

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bioxcell.com

(1) Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discoveryOncoimmunologyJanuary 1, 2019Sivakumar R, Chan M, Shin JS, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS.

(2) Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodiesClinical cancer research : an official journal of the American Association for Cancer ResearchMarch 1, 2015Dai M, Yip YY, Hellstrom I, Hellstrom KE.

(3) Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatmentCancer immunology researchMarch 1, 2015Zippelius A, Schreiner J, Herzig P, Müller P.

(4) Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cellsCancer immunology researchAugust 1, 2014Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, et al.

(5) ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosisThe Journal of clinical investigationJune 1, 2014Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, et al.

(7) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesThe Journal of experimental medicineAugust 26, 2013Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL.

(8) Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammationJournal of immunotherapy (Hagerstown, Md. : 1997)May 1, 2013Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE.

(11) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature medicineAugust 28, 2011Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al.

InVivoPlus anti-mouse CTLA-4 (CD152)